share_log

Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35

Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35

古根海姆以買入評級啓動對Immunome的報道,宣佈目標股價爲35美元
Moomoo 24/7 ·  04/15 06:34

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $35.

古根海姆分析師邁克爾·施密特以買入評級開始對Immunome(納斯達克股票代碼:IMNM)進行報道,並宣佈目標股價爲35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論